• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Similar real-world two-year visual acuity gains in treatment-naive patients with diabetic macular oedema treated with a loading dose of three initial monthly injections versus less intensive regimens of intravitreal anti-vascular endothelial growth factor.

作者信息

Lindboe Johanne Bjerre, Schmidt Laugesen Caroline, Sørensen Torben Lykke, Brynskov Troels

机构信息

Clinical Eye Research Division, Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark.

Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

出版信息

Acta Ophthalmol. 2021 Nov;99(7):e1248-e1249. doi: 10.1111/aos.14724. Epub 2021 May 6.

DOI:10.1111/aos.14724
PMID:33956397
Abstract
摘要

相似文献

1
Similar real-world two-year visual acuity gains in treatment-naive patients with diabetic macular oedema treated with a loading dose of three initial monthly injections versus less intensive regimens of intravitreal anti-vascular endothelial growth factor.在初治糖尿病性黄斑水肿患者中，与玻璃体腔内抗血管内皮生长因子的较不强化治疗方案相比，采用初始每月注射三次的负荷剂量治疗，两年时的视力在现实世界中的改善情况相似。
Acta Ophthalmol. 2021 Nov;99(7):e1248-e1249. doi: 10.1111/aos.14724. Epub 2021 May 6.
2
Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.玻璃体内注射阿柏西普治疗糖尿病性黄斑水肿：摩尔费尔德眼科医院的12个月真实世界视力及解剖学结果
Eur J Ophthalmol. 2020 May;30(3):557-562. doi: 10.1177/1120672119833270. Epub 2019 Feb 26.
3
Real-world experiences with intravitreal treatment with ranibizumab and aflibercept for diabetic macular oedema 2008-2021.2008年至2021年雷珠单抗和阿柏西普玻璃体内注射治疗糖尿病性黄斑水肿的真实世界经验
Acta Ophthalmol. 2024 Jun;102(4):e661-e662. doi: 10.1111/aos.16677. Epub 2024 Mar 25.
4
IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.长期玻璃体内抗血管内皮生长因子治疗对糖尿病性黄斑水肿中预先存在的微观结构改变的影响。
Retina. 2018 Sep;38(9):1824-1829. doi: 10.1097/IAE.0000000000001788.
5
Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy.抗血管内皮生长因子治疗后预测糖尿病黄斑水肿治疗效果的高反射焦点。
Sci Rep. 2021 Mar 3;11(1):5103. doi: 10.1038/s41598-021-84553-7.
6
OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study.光学相干断层扫描基线预测因子与糖尿病性黄斑水肿眼玻璃体内抗血管内皮生长因子治疗的初始最佳矫正视力反应：CHARTRES 研究。
Retina. 2018 Jun;38(6):1110-1119. doi: 10.1097/IAE.0000000000001687.
7
One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.在初治糖尿病性黄斑水肿患者中使用无负荷期的抗VEGF药物治疗并延长方案的一年结果
Ophthalmologica. 2019;241(4):220-225. doi: 10.1159/000495623. Epub 2019 Jan 17.
8
Task shifting of intraocular injections from physicians to nurses: a randomized single-masked noninferiority study.将眼内注射从医师转移到护士：一项随机单盲非劣效性研究。
Acta Ophthalmol. 2020 Mar;98(2):139-144. doi: 10.1111/aos.14184. Epub 2019 Jul 3.
9
Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.抗血管内皮生长因子药物治疗反应良好的黄斑水肿患者每月给药方案与治疗-延长方案的比较：SCORE2随机临床试验的次要结果
JAMA Ophthalmol. 2018 Apr 1;136(4):337-345. doi: 10.1001/jamaophthalmol.2017.6843.
10
Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes.玻璃体内注射雷珠单抗治疗既往已行玻璃体切割术的糖尿病性黄斑水肿。
Acta Ophthalmol. 2017 Feb;95(1):28-32. doi: 10.1111/aos.13160. Epub 2016 Jul 30.